Abeona治疗公司CFO在2026年1月22日出售股票,因为尽管季度亏损,股票略有上升。 Abeona Therapeutics' CFO sold shares on Jan. 22, 2026, as stock rose slightly despite quarterly loss.

2026年1月22日, Abeona治疗学公司(ABEO)CFO Joseph Walter Vazzano出售18 666股,每股5.33美元,共计99 490美元,股份减少3.18%,达到568 560股。 On January 22, 2026, Abeona Therapeutics (ABEO) CFO Joseph Walter Vazzano sold 18,666 shares at $5.33 each, totaling about $99,490, reducing his stake by 3.18% to 568,560 shares. 该公司的股票以5.36美元关闭,增加了5美元,交易额为136万股。 The company’s stock closed at $5.36, up $0.05, with trading volume of 1.36 million shares. Abeona是一家设在克利夫兰的生物制药公司,报告每季度每股损失0.10美元,击败估计数为0.17美元。 Abeona, a Cleveland-based biopharma firm, reported a quarterly loss of $0.10 per share, beating estimates by $0.17. 分析员预期全年损失为1.16美元。 Analysts expect a full-year loss of $1.16. 该股票的市值为2.9046亿美元,债务与股权比为0.06,共识性"中等买入"评级为20.00美元. The stock has a market cap of $290.46 million, a debt-to-equity ratio of 0.06, and a consensus “Moderate Buy” rating with a $20.00 target.